The Effect of Non-invasive Brain Stimulation on Language Production in Post-stroke Aphasia

Sponsor
King's College London (Other)
Overall Status
Completed
CT.gov ID
NCT04204356
Collaborator
(none)
6
1
2
11.4
0.5

Study Details

Study Description

Brief Summary

Aphasia is a language impairment caused by brain injury such as stroke that affects the ability to understand and express language, read and write due to damage in the language regions of the brain. Non-invasive brain stimulation (NIBS) techniques like transcranial direct-current stimulation (tDCS) have been found to improve aphasia treatment effects in post stroke patient populations such as improved naming abilities.

However, the effect of tDCS on more functional, higher level language skills such as discourse production (i.e. story telling, giving instructions) has yet to be understood.Therefore the aim of this study is to determine the potential effectiveness of tDCS as an adjunct to speech and language therapy (SLT) to improve discourse speech production in people with post-stroke aphasia. It is hypothesised that SLT combined with tDCS will result in greater improvements in discourse language production compared to SLT on its own.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Language treatment for improving discourse production
  • Device: Transcranial direct-current stimulation (tDCS)
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
6 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Effect of Speech and Language Therapy With and Without Transcranial Direct-current Stimulation on Discourse Production in People With Post-stroke Aphasia: a Pilot Randomised Controlled Trial
Actual Study Start Date :
Nov 25, 2019
Actual Primary Completion Date :
Aug 28, 2020
Actual Study Completion Date :
Nov 5, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: tDCS group

Participants randomly allocated to this group using a random number generator will receive a once weekly, 6-week block of language treatment with active tDCS.

Behavioral: Language treatment for improving discourse production
All participants will receive a 6-week block of language treatment for improving verb retrieval in discourse production by a professional speech and language therapist. The treatment goals for this block of treatment are to 1) improve verb retrieval and language quantity and complexity in discourse production 2) improve functional communication skills and; 3) improve quality of life and psychological state in people with post-stroke chronic aphasia.

Device: Transcranial direct-current stimulation (tDCS)
Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. The use of tDCS as an adjunct to speech and language therapy has been found to improve aphasia treatment effects in post stroke patient populations.

Sham Comparator: Sham group

Participants randomly allocated to this group using a random number generator will receive a once weekly, 6-week block of language treatment without active tDCS (sham)

Behavioral: Language treatment for improving discourse production
All participants will receive a 6-week block of language treatment for improving verb retrieval in discourse production by a professional speech and language therapist. The treatment goals for this block of treatment are to 1) improve verb retrieval and language quantity and complexity in discourse production 2) improve functional communication skills and; 3) improve quality of life and psychological state in people with post-stroke chronic aphasia.

Outcome Measures

Primary Outcome Measures

  1. Verb token total [30 minutes]

    The number of all verb occurrences in a language sample

  2. Verb type total [30 minutes]

    The number of distinct verbs in a sample

Secondary Outcome Measures

  1. Total number of words [30 minutes]

    The total number of words in a language sample

  2. Total number of utterances [30 minutes]

    The total number of utterances in a language sample

  3. Predicate argument structure (PAS) [30 minutes]

    The main verbs and their arguments will be identified in each sentence within a language sample. A PAS complexity score will be calculated using the formula: number of arguments/number of main verbs

  4. Communicative Effectiveness Index (CETI) [10 minutes]

    CETI is a valid and reliable measure of change in functional communication ability in adults with aphasia. This assessment includes 16 everyday situations such as having a one to one conversation and giving yes or no answers appropriately. Participants are asked to rate their ability in each particular communication situation using a rating scale with one end labelled as 'not at all able and the other 'as able as before

  5. Aphasia Impact Questionnaire-21 (AIQ) [15 minutes]

    AIQ is a self-report questionnaire which utilises pictures to enable people with aphasia to communicate their experiences of aphasia. There are 8 questionnaires to select from with scales that vary in relation to gender and race. Pictorial responses can be translated into numerical scores, and then documented on a summary score sheet. The questionnaire has three sections; communication, participation and well-being/emotional state. The first section looks at activities which are commonly difficult for people with aphasia such as talking and understanding. The participation section looks at how communication difficulties arising from aphasia impact the person's ability to complete tasks in everyday life such as shopping and work. The last section looks at the emotional effect of aphasia.

  6. Hospital Anxiety and Depression Scale (HADS) [10 minutes]

    HADS is a 14-item scale which assesses non-somatic anxiety and depression symptoms. Scores range from 0 to 21 for each sub-scale with a score ≥8 proposed for the identification of caseness, for both depression and anxiety.

  7. Montreal Cognitive Assessment (MoCA) [15 minutes]

    The MoCA is a brief and easy to administer cognitive assessment. Different aspects of cognition such as memory, executive function, language, visual-spatial ability and orientation are assessed. Scores range from 0-30, where the recommended cut-off score for identifying multi-domain cognitive impairment in persons with chronic stroke is 20/30.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • aphasia caused by a single stroke

  • at least 6 months post stroke

  • at least 18 years old

  • competent English speaker prior to stroke

  • right handed prior to stroke

  • normal aided or unaided visual acuity

  • willing to participate and to comply with the proposed block of intervention and testing regime.

Exclusion Criteria:

Persons with

  • neurological symptoms or history of a neurological event other than their stroke

  • contraindications to tDCS including history of epilepsy or seizures and pacemakers

  • global/severe aphasia

  • cognitive impairment identified by a score less than 20/30 in the Montreal Cognitive Assessment

  • left-handed dominance prior to stroke

  • visual problems which interfere with persons' ability to access visual materials (i.e. pictures)

  • inability to attend sessions

Contacts and Locations

Locations

Site City State Country Postal Code
1 King's College London London United Kingdom SE1 1UL

Sponsors and Collaborators

  • King's College London

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
King's College London
ClinicalTrials.gov Identifier:
NCT04204356
Other Study ID Numbers:
  • HR-19/20-12921
First Posted:
Dec 18, 2019
Last Update Posted:
Feb 18, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 18, 2021